Featured Research

from universities, journals, and other organizations

Dementia: Cerebrolysin shows promise

Date:
January 31, 2013
Source:
Wiley
Summary:
Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

Dementia patients may benefit from a promising new treatment called Cerebrolysin, according to the results of a systematic review published in The Cochrane Library. The authors brought together the most up-to-date evidence on Cerebrolysin as a treatment for vascular dementia.

Related Articles


Vascular dementia is a common form of dementia caused by damage to the network of blood vessels supplying the brain. Some of the symptoms are similar to those associated with Alzheimer's disease and stroke but in particular those with vascular dementia often experience difficulty thinking quickly, concentrating and communicating, as well as seizures and severe confusion. There is currently no definitive treatment for vascular dementia. Cerebrolysin is a drug treatment made from pig brain proteins that has produced positive results against vascular dementia, although inconsistently.

The researchers reviewed data from six randomized controlled trials involving 597 people in total. All were given Cerebrolysin intravenously in different daily concentrations and for different treatment periods, from a few weeks to three years, depending on the trial. Compared to standard care alone or placebos, Cerebrolysin significantly improved cognitive function, which was assessed with scales testing recall, arithmetic or other cognitive abilities. It had a small positive effect on patients' overall clinical state. There was also some suggestion that long-term treatment was associated with greater benefits, although only two trials looked at long-term effects.

"Our review suggests that Cerebrolysin can help improve cognitive and global function in patients with mild to moderate severity vascular dementia," said researcher Li He of the Department of Neurology at Sichuan University in Sichuan, China. "The results are promising but due to low numbers of trials, inconsistencies between trials, risk of bias in the way some of the trials were conducted and lack of long-term follow-up, we cannot yet recommend Cerebrolysin as a routine treatment for vascular dementia."

None of those involved in studies reported serious side effects due to taking the drug and non-serious side effects were no more common in those who took the drug compared to control groups. "This indicates to us that Cerebrolysin is safe and well tolerated by patients with vascular dementia," said He. "But the fact that it has to be given in regular intravenous infusions means it could be impractical for use on a large scale."


Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.


Journal Reference:

  1. Ning Chen, Mi Yang, Jian Guo, Muke Zhou, Cairong Zhu, Li He. Cerebrolysin for vascular dementia. The Cochrane Library, 2013; DOI: 10.1002/14651858.CD008900.pub2

Cite This Page:

Wiley. "Dementia: Cerebrolysin shows promise." ScienceDaily. ScienceDaily, 31 January 2013. <www.sciencedaily.com/releases/2013/01/130131084614.htm>.
Wiley. (2013, January 31). Dementia: Cerebrolysin shows promise. ScienceDaily. Retrieved November 20, 2014 from www.sciencedaily.com/releases/2013/01/130131084614.htm
Wiley. "Dementia: Cerebrolysin shows promise." ScienceDaily. www.sciencedaily.com/releases/2013/01/130131084614.htm (accessed November 20, 2014).

Share This


More From ScienceDaily



More Mind & Brain News

Thursday, November 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Kids React to Lammily, The Realistic Barbie Alternative

Kids React to Lammily, The Realistic Barbie Alternative

Buzz60 (Nov. 19, 2014) Artist Nickolay Lamm's Kickstarter-funded Lammily doll, based on his 'What Would Barbie Look Like as a Real Woman' project, is finally available to buy. Jen Markham explains how the doll's realistic proportions are going over with a test group of second-graders who are used to the impossible measurements of Barbie dolls. Video provided by Buzz60
Powered by NewsLook.com
Trans-Fat Foods Now Linked To Poor Memory

Trans-Fat Foods Now Linked To Poor Memory

Newsy (Nov. 19, 2014) A study presented at the American Heart Association Scientific Sessions shows a link between diets high in trans fats and decreased memory recall. Video provided by Newsy
Powered by NewsLook.com
Creating Lifelong Love of Science and Math

Creating Lifelong Love of Science and Math

AP (Nov. 18, 2014) Kelly Mathews is a new mom on a mission to get girls interested in science, technology, engineering and math, and it starts with her own daughter. The Girl Scouts are doing their part, too, by promoting S.T.E.M. through badges and activities. (Nov. 18) Video provided by AP
Powered by NewsLook.com
3D Fun Improves Child Therapy in Poland

3D Fun Improves Child Therapy in Poland

Reuters - Innovations Video Online (Nov. 17, 2014) Scientists in Poland are helping children with autism and Down's Syndrome better focus on therapeutic exercises by taking them out of their real world environment and into a specially-designed 3D cave in which their imagination can flourish. Jim Drury reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins